Eterna Therapeutics
ERNA
9 hedge funds and large institutions have $236K invested in Eterna Therapeutics in 2026 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 9 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
2.56% more ownership
Funds ownership: 0.49% → 3.05% (+2.6%)
40% less funds holding
Funds holding: 15 → 9 (-6)
67% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 9
67% less capital invested
Capital invested by funds: $711K → $236K (-$475K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$97.9K |
| 2 |
Vanguard Fiduciary Trust
Malvern,
Pennsylvania
|
+$52K |
| 3 |
Vanguard Capital Management
Malvern,
Pennsylvania
|
+$32.9K |
| 4 |
TCM
Tradewinds Capital Management
Bellingham,
Washington
|
+$2.56K |
| 5 |
BNP Paribas Financial Markets
Paris,
France
|
+$7 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BL
Bleichroeder LP
New York
|
-$398K |
| 2 |
DIG
Dauntless Investment Group
Etna,
New Hampshire
|
-$131K |
| 3 |
Corient Private Wealth
Miami,
Florida
|
-$87.2K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$48.6K |
| 5 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$10.8K |
ERNA Hedge Fund Activity: Q2 2026 in Review
9 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in Eterna Therapeutics (ERNA) for Q2 2026, worth a combined $236K — down 67% from $711K a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of ERNA and 3 opened new positions — a net loss of 6 holders — while 1 trimmed existing stakes and 3 added.
The largest buyer was Citadel Advisors, adding an estimated $97.9K. The largest seller was Bleichroeder LP, exiting entirely with an estimated $398K sold.
- 9 institutional investors held Eterna Therapeutics (ERNA) as of Q2 2026, down from 15 in Q1 2026.
- Funds reported $236K of Eterna Therapeutics stock for Q2 2026, down 67% quarter-over-quarter.
- 3 funds opened new Eterna Therapeutics positions in Q2 2026 and 9 closed out, a net change of -6 holders.
- The largest Eterna Therapeutics buyer in Q2 2026 was Citadel Advisors, an estimated $97.9K added.
- The largest Eterna Therapeutics seller in Q2 2026 was Bleichroeder LP, an estimated $398K sold.
Based on aggregated 13F filings for Q2 2026.